The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer

SLC7A11/xCT is an antiporter that mediates the uptake of extracellular cystine in exchange for glutamate. Cystine is reduced to cysteine, which is a rate-limiting precursor in glutathione synthesis; a process that protects cells from oxidative stress and is, therefore, critical to cell growth, proliferation, and metabolism. SLC7A11 is expressed in different tissues and plays diverse functional roles in the pathophysiology of various diseases, including cancer, by regulating the processes of redox homeostasis, metabolic flexibility/nutrient dependency, immune system function, and ferroptosis. SLC7A11 expression is associated with poor prognosis and drug resistance in cancer and, therefore, represents an…

• VU
  Vanderbilt University
• VC
  Vanderbilt-Ingram Cancer Center

  Awards: DK058404, 5P30 CA068485, CA068485
• NC
  National Cancer Center
• AG
  American Gastroenterological Association

  Award: AGA2021-13
• SF
  Sky Foundation
• NI
  National Institutes of Health

  Awards: 5P30 CA068485, CA068485, 5P30 DK058404, DK058404
• VD
  Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center

  Awards: NIH/NCI 5P50 CA236733, DK058404
• NC
  National Cancer Institute

  Awards: CA068485, CA236733
• NI
  National Institute of General Medical Sciences
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases

  Award: DK058404